PPR-163 - Pembrolizumab Improves Survival in Advanced Triple-Negative Breast Cancer Compared to Chemotherapy Alone: A Multi-Centre Retrospective Study

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: PPR-163
• By: OMAR ATIA, Ebtehal Elsayed (IPSF / Dar Alfouad Hospital, Egypt)
• Co-author(s): Dr Ebtehal Elsayed Omar Atia (IPSF / Dar Alfouad Hospital, Giza, Egypt)
  
• Abstract:

  Introduction:
  Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen, progesterone, and HER2 receptors, limiting therapeutic options to cytotoxic chemotherapy. Pembrolizumab, a PD-1 checkpoint inhibitor, has shown potential benefit in advanced TNBC with high PD-L1 expression. This study evaluates the impact of adding..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login